Shots:

• The NDA submission is based P-II CodeBreaK 100 study assessing Sotorasib in patients with KRAS G12C-mutated NSCLC prior treated with CT and immunotherapy
• The study provided durable anticancer activity with a positive benefit-risk profile
• The US FDA has reviewed the NDA under RTOR pilot program- which aims to explore efficient review process that ensures safe and effective treatments are made available to patients as early as possible

 ­ Ref: PRNewswire | Image: Axios